Pioneering The Development of Novel Precision Oncology Drugs Targeting Stress Support Pathways

Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways using our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform.

Learn More

Our Proprietary BEACON+ Platform

We have created our proprietary BEACON+ platform to unlock the biochemical roles of NAD+-utilizing enzymes and to discover and develop small molecules for the treatment of cancer.

Learn More

RBN-2397 – PARP7 Inhibitor

Developing our lead product candidate, RBN-2397, as a potent, selective and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors.

Learn More
July 22

Cambridge, MA

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Learn More
Join our team of experts.
Find Out More